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Abstract. For most if not all cancers, prognosis is of significant importance, and extensive modeling
research has been conducted. With the genetic nature of cancer, in the past two decades, multiple types of
molecular data (such as gene expressions and DNA mutations) have been explored. More recently,
histopathological imaging data, which is routinely collected in biopsy, has been shown as informative for
modeling prognosis. In this study, using the TCGA LUAD and LUSC data as a showcase, we examine
and compare modeling lung cancer overall survival using gene expressions versus histopathological
imaging features. High-dimensional regularization methods are adopted for estimation and selection. Our
analysis shows that gene expressions have slightly better prognostic performance. In addition, most of the
gene expressions are found to be weakly correlated imaging features. It is expected that this study can
provide some insight into utilizing the two types of important data in cancer prognosis modeling and into
lung cancer overall survival.
Keywords: Cancer prognosis modeling; molecular changes; histopathological imaging features;
high-dimensional regularized estimation.
21. Introduction
For most if not all cancers, various prognosis outcomes, such as overall survival, progression free survival,
and time to metastasis, are of essential importance. Accordingly, extensive modeling research has been
conducted. In “classic” prognosis studies, low-dimensional demographic, clinical, and environmental risk
factors are analyzed, and “standard” regression-based techniques (such as Cox model) are usually
sufficient. Despite some successes, it has been well recognized that the complexity of cancer prognosis
demands additional data and more sophisticated modeling.
Cancer is a genetic disease. In the past two decades, with the fast development of high-throughput
sequencing techniques, molecular data have been extensively collected in cancer studies, and accordingly,
molecular data-based prognosis modeling has been accumulating. For example, an investigation of
miRNA expression in 104 pairs of primary lung cancers and corresponding noncancerous lung tissues
found that high hsa-mir-155 and low hsa-let-7a-2 expressions are correlated with poor survival of lung
cancer. The signatures were cross validated using an independent set of adenocarcinomas 1. Since then,
hsa-mir-155 over expression has been reported in thyroid carcinoma, breast cancer, colon cancer, and
cervical cancer, indicating its potential for serving as a biomarker for tumor detection and evaluation of
prognosis outcome 2. As another example, the study of genome-wide expression of 100 Non–Small-Cell
lung cancer (NSCLC) FFPE samples identified a signature composed of 59 genes, which was strongly
associated with prognosis for stage I lung cancer patients. This signature was later proven to be robust for
clinical usage 3. Molecular data are high-dimensional and contain substantial “noises”, that is, the
majority of measurements are not associated with prognosis. To effectively remove noises, identify
relevant effects, and build reliable models using “signals” only, a myriad of high-dimensional statistical
techniques has been developed. A popular family of approaches conducts regularization and applies
techniques such as penalization, boosting, Bayesian, and thresholding, which can simultaneously achieve
estimation and variable selection. Such techniques have demonstrated statistical, numerical, and empirical
3successes. We refer to published literature 4-6 for reviews and more extensive discussions. With the
accumulation of clinical and experimental data, there is increasing knowledge on the functionality of
molecular changes. As such, studies have also been conducted using molecular changes that have “prior
information”, for example, with evidence of being relevant from multiple studies. In this line of work,
multiple gene panels have been developed. For example, Jablons and colleagues aimed at developing a
prognostic risk score for patients with completely resected lung adenocarcinomas based on genes
previously identified in microarray models of NSCLC prognosis. They suggested narrowing the 61-gene
panel down to 4 genes 7. A drawback of molecular data is that it is not as easy to collect: many patients
are still concerned with providing tissues for molecular profiling, and the cost of high-throughput
profiling is still not “friendly”.
A more recent type of data comes from histopathological imaging. In cancer clinical practice, biopsy is
routinely conducted, which generates histopathological images. Such images have been long used for
definitive diagnosis and staging 8. They contain rich information on tumors’ “micro” properties and
surrounding microenvironment, which play important roles in cancer development. In a handful of recent
studies, histopathological imaging features have been used for modeling cancer prognosis (as well as
other outcomes and phenotypes) 9,10. However, such studies are still relatively limited. With the
consideration that tumor properties can be affected by molecular changes, there have been studies
modeling the relationships between imaging features and molecular changes 11,12. Considering the
cost-effectiveness and routineness of biopsy and histopathological images, imaging-based modeling, if
effective, can have great potential. Here we distinguish between histopathological images and radiological
images – the latter are generated by CT, PET, and other radiological techniques and inform “macro”
properties of tumors such as size, shape, and density.
A common limitation of the existing studies is that information has been scattered. More specifically,
studies that analyze both histopathological imaging features and molecular changes using the same data
4and on the same ground are very limited. With differences in patient characteristics and data generation,
processing, and analysis procedures, findings from different studies may not be directly comparable.
The objective of this theoretical study is multi-fold. Specifically, it intends to further demonstrates cancer
prognosis modeling using histopathological imaging and molecular data, taking advantage of
high-dimensional regularization techniques. More importantly, it provides a direct and fair comparison of
modeling using these two types of highly important and popular data. To be comprehensive, we also
move on and examine integrating these two types of data for modeling prognosis as well as modeling
their relationships. With the analysis of TCGA LUAD and LUSC data, this study may also provide
additional insight into lung cancer prognosis.
2. Materials
TCGA (The Cancer Genome Atlas) is one of the largest and most comprehensive cancer projects
organized by the NCI (National Cancer Institute) and NHGRI (National Human Genome Research
Institute). For over thirty different types of cancer, it has published comprehensive phenotypic,
demographic, molecular, and imaging data 13. We choose to analyze TCGA data because of its high
quality, comprehensiveness, and public availability. In particular, we analyze data on LUAD (lung
adenocarcinoma) and LUSC (lung squamous cell carcinoma), two subtypes of NSCLC. Lung cancer
patients in general have poor prognosis, and as such, prognosis modeling can be especially important. For
prognosis outcome, we choose overall survival, which has also been analyzed in Radzikowska, et al. 14,
Collins, et al.15, and quite a few other studies.
Figure 1. Pipeline for extracting imaging features
52.1 Histopathological imaging data
Whole-slide histopathology images are downloaded from the TCGA website (http://portal.gdc.cancer.gov)
and are in the svs format. These tissue slides are formalin-fixed and paraffin-embedded, and the cell
morphology is well-preserved and suitable for image feature recognition. They are captured at 20* or 40*
magnification by the Aperio medical scanner. In recent studies, we 12 and others 16,17 have developed and
implemented a pipeline for extracting high-dimensional imaging features, which is sketched in Figure 1.
Briefly, it includes the following three main steps. First, whole-slide histopathology images are chopped
into small subimages of 500*500 pixels, and 20 subimages are randomly selected from the whole slide
image. Then, imaging features are extracted using CellProfiler 18, a publicly available software that has
been adopted in quite a few recent studies 10,19,20. In the next step, for each patient, features are averaged.
We refer to Zhong, et al.12 and Luo, et al.16 for more detailed discussions on this imaging processing
pipeline as well as alternatives. With this processing pipeline, as many as 299 features can be obtained.
We note that this is significantly higher than in studies such as Wang, et al.21 and Romo, et al.22, which
consider low-dimensional imaging features. Comparatively, high-dimensional features have less lucid
interpretations but can contain more information and be more powerful in modeling. As such, they are
adopted in this analysis. With the extracted features, we further conduct quality control. In particular,
irrelevant features, such as file size and execution information, are removed. We also remove features
with severe missingness (>25%) and no or little variation. A total of 221 features are included in
downstream analysis.
2.2 Molecular data
For molecular data, we analyze gene expressions, which have been considered in many lung cancer
prognosis modeling studies 23,24. Compared to DNA and epigenetic changes, gene expressions are “closer”
to phenotypes. With a lack of high-quality protein data, TCGA gene expression data have been
extensively analyzed for prognosis and other phenotypes and biomarkers. In TCGA, gene expressions
were measured using the Illumina Hiseq2000 RNA Sequencing Version 2 analysis platform and
6processed and normalized using the RSEM software. More detailed information is available in the
literature 25,26. It is possible to directly conduct whole transcriptome analysis. However, findings may be
unreliable when sample sizes are limited. As such, we take a candidate gene approach. In particular, the
61 gene panel developed in Raz, et al. 7 is adopted. Matching this panel with gene names in the TCGA
data leads to 50 genes for analysis. We acknowledge that there is still a lack of definitive consensus on
lung cancer prognosis genes and that there are other lung cancer prognosis gene panels. This particular
panel is selected as it has been recently examined in authoritative studies. The proposed analysis can be
directly applied to other prognosis panels.
2.3 Available data
Beyond imaging and gene expression data, clinical characteristics have also been established as
associated with prognosis and included in our analysis. Following published studies and considering data
availability, we include sex, age, cancer stage, and tumor size. More specifically, tumor size is defined as
longest dimension*shortest dimension, and we combine cancer stages into three levels to avoid small
counts. Multiple types of data are combined by matching unique sample IDs. The final LUAD data
contains 307 samples. Among them, 106 died, with survival times ranging from 0 to 88.07 months and a
median of 20.52 months. There are also 201 censored subjects, with observed times ranging from 0 to
238.11 months and a median of 23.16 months. The final LUSC data contains 334 samples. Among them,
155 died, with survival times ranging from 0.10 to 173.69 months and a median of 18.36 months. There
are also 179 censored subjects, with observed times interval ranging from 0.39 to 156.54 months and a
median of 23.55 months. For both LUAD and LUSC, data on 221 histopathological imaging features and
50 gene expressions are available. Summary statistics on the clinical characteristics are presented in Table
1.
7Table 1. Summary of clinical characteristics.
LUAD (n=307) LUSC (n=334)
Sex
Female 170 Female 85
Male 137 Male 249
Age 65.49(sd=9.71) 67.38(sd=8.59)
Cancer
Stage
Stage I 3
Level_A(164)
Stage I 1
Level_A(176)Stage IA 73 Stage IA 60
Stage IB 88 Stage IB 115
Stage II 0
Level_B(77)
Stage II 1
Level_B(93)Stage IIA 28 Stage IIA 33
Stage IIB 49 Stage IIB 59
Stage III 0
Level_C(66)
Stage III 0
Level_C(65)
Stage IIIA 40 Stage IIIA 46
Stage IIIB 7 Stage IIIB 14
Stage IV 19 Stage IV 5
Tumor
Size
0.467(sd=0.324) 0.470(sd=0.309)
3. Analysis techniques
Denote T and C as the event and censoring times, respectively. With right censoring, we observe   u
min  䟸ඟ 䟸  u 耀     ඟ . Denote   as the  -dimensional vector of histopathological imaging features,
  as the   -dimensional vector of gene expressions, and   as the   -dimensional vector of clinical
characteristics. Assume   iid samples.
3.1 Associate histopathological imaging features and gene expressions with survival
Here our goal is to conduct various “standard” survival analysis and associate imaging features and/or
gene expressions with overall survival, while properly accounting for the effects of clinical characteristics.
We comprehensively consider multiple sets of analysis.
First consider the analysis with    u   䟸  
 
as input. Consider the Cox model, under which the hazard
function:
8       u      exp  
     
Here      is the unknown baseline hazard function, and   is the vector of unknown regression
coefficients. Consider the log partial likelihood function:
    u  u 䟸 䟸     
   
    log  u 䟸 䟸 exp  
   
          ,
where subscripts   and   correspond to subjects   and  , and       is the subject  ’s at risk indicator at
time    . To accommodate the high data dimensionality, and to remove noises and identify relevant
effects, we consider the Lasso penalized estimate:
   u arg max        
 u 䟸  䟸 
    䟸
where       is the data-dependent tuning parameter and chosen using cross-validation, and    is the  th
component of  . Here it is noted that penalization is only imposed on the imaging features. As such, the
clinical variables are automatically included, given their established importance in lung cancer prognosis.
For a specific imaging feature, a nonzero estimate suggests its association with survival. Literature review
suggests that penalization is one of the most popular techniques for accommodating high-dimensional
input and feature selection, and Lasso is likely the most popular penalization technique. The adopted
“Cox model + Lasso estimation” approach has been examined in multiple published studies 27,28. In our
analysis, it is realized using the R package “glmnet”. We note that analysis can also be conducted using
other penalties and regularization techniques other than penalization, and that analysis results depend on
the adopted technique.
Next we consider the analysis with    u   䟸  
 
as input. Analysis can be conducted in the same
manner as for imaging features. Denote   as the vector of unknown regression coefficients in the Cox
model and   as its Lasso penalized estimate. Note that the baseline hazard functions in this and the
above analysis may be different. In this analysis, although the genes have been pre-selected, it is still
necessary to apply penalization. In particular, the number of variables, relative to the sample size, is still
large. As such, certain regularization is needed in estimation. In addition, to be “cautious”, it may still be
9sensible to examine whether all genes in the panel are associated with survival for the particular TCGA
patient cohort (which may differ from those examined in published studies).
In the next set of analysis, we integrate the imaging features and gene expressions using a simple additive
approach. In particular, we consider a Cox model with input variable    䟸 䟸     䟸   䟸 䟸    䟸 
    .
Prior to model fitting, we compute the correlation coefficient between    䟸 䟸      and   䟸 䟸     ,
which can suggest whether the two types of data have overlapping information in modeling survival (after
adjusting for the clinical variables). In model fitting, as the dimensionality is low, we do not impose any
penalization. This analysis takes a simple additive modeling strategy, which has been developed in the
literature 19 and shown as reasonably effective in data integration. It retains the “structure” of imaging
effects and that of gene expressions.
For the above three sets of survival analysis, we adopt a random splitting approach to evaluate prediction
performance: (a) Randomly split all samples into a training and a testing set with sizes roughly 3:1; (b)
Conduct survival analysis as described above using the training set; (c) For subjects in the testing set,
compute the predicted risk scores. For example, for the analysis with imaging features, the risk scores are
       . Compute the C-index using the predicted risk scores and testing set (observed time, event
indicator). The C-index ranges between 0 and 1, with a larger value indicating better prediction. It is also
the time-integrated AUC (Area under the Receiver Operating Characteristic curve). To avoid an extreme
split, Steps (a)-(c) are repeated 100 times, and the average C-index is computed to quantify prediction
performance. The goal of this analysis is two-fold. The first is to directly compare prognostic
performance of the imaging-based model versus that of the gene expression-based. In addition, this
analysis also examines whether integrating the two distinct types of measurements can further improve
prediction performance.
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3.2 Associate gene expressions with histopathological imaging features
Tumor properties and surrounding microenvironment are reflected in histopathological images and at
least partially regulated by molecular changes. In this sense, imaging features and molecular changes
should be interconnected. In recent literature, there have been a handful of studies examining their
relationship 12,17. Such analysis can directly suggest whether the two types of data have overlapping
information and its degree. Note that this analysis is “unsupervised”, does not involve survival, and can
more broadly suggest overlapping information than the correlation analysis above.
Consider the model:
  u       䟸
where   is the       matrix of regression coefficients, and   is the  -dimensional vector of random errors.
Here we model the “downstream” imaging features using the “upstream” gene expressions. Linear
regression model is adopted with the consideration that more complex modeling may not be reliable with
the limited sample size and high dimensionality of both sides of modeling. For estimating  , consider:
  u arg min
 u 䟸 䟸 
          
     
 u 䟸 䟸 
       䟸
where subscript   corresponds to subject  ,       is a data-dependent tuning parameter and chosen using
cross-validation,     is the  th row of  , and     is the    norm. Here to accommodate the high data
dimensionality and select gene expressions that are relevant for imaging features, we apply the group
Lasso penalization.
Similar as above, to more objectively evaluate the relationship, we consider the following approach: (a)
Randomly split data into a training and a testing set in the same way as above; (b) Conduct the group
Lasso estimation using the training set; (c) For the testing set subjects, predict imaging feature values
using gene expressions and the training set estimate. For each imaging feature, compute the correlation
coefficient between the predicted and estimated values; (d) To avoid an extreme split, repeat Steps (a)-(c)
11
100 times, and compute the average correlation values. We note that penalization may introduce
shrinkage towards zero. As such, we adopt correlation coefficient as the criterion, which is less affected
by shrinkage.
4. Results
4.1 Comparison of modeling using histopathological imaging features or gene expressions
The first set of analysis regresses survival on the imaging features and clinical characteristics. For the
variables included in the final models, their estimated regression coefficients are shown in Tables 2
(LUAD) and 3 (LUSC), respectively. In particular, beyond the clinical characteristics, 7 and 9 imaging
features are identified, representing AreaShape, Texture, Granularity, and other characteristics. It has
been noted in the literature that, unlike omics and some other types of data, high-dimensional imaging
features do not have lucid functional interpretations. As such, we do not further pursue bioinformatics
interpretations.
Table 2. Analysis of LUAD data: identified imaging features and clinical characteristics associated with
overall survival and their estimated coefficients.
Imaging feature Coef
Clinical
characteristic
Coef
AreaShape_Zernike_6_4 0.3697 Sex -0.0245
AreaShape_Zernike_8_6 0.0426 Age 0.0095
AreaShape_Zernike_9_7 0.1409 Tumor_Size 0.1154
Count_identifytissueregion 0.1759 Stage_Level_A -1.2100
Neighbors_AngleBetweenNeighbors_Adjacent -0.1033 Stage_Level_B -0.2976
Neighbors_FirstClosestObjectNumber_Adjacent -0.2527 Stage_Level_C NA
Threshold_WeightedVariance_identifyhemaprima
rynuclei
-4.04E-05
Table 3. Analysis of LUSC data: identified imaging features and clinical characteristics associated with
overall survival and their estimated coefficients.
Imaging feature Coef
Clinical
characteristic
Coef
AreaShape_EulerNumber -0.1575 Sex 0.5259
ObjectNumber -0.2416 Age 0.0231
Granularity_12_ImageAfterMath 0.2382 Tumor_Size -0.0369
Threshold_SumOfEntropies_identifytissueregion 0.1466 Stage_Level_A -0.7496
Location_Center_X.1 -0.0812 Stage_Level_B -0.4852
AreaShape_Center_X -0.0903 Stage_Level_C NA
AreaShape_Orientation -0.0985
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Neighbors_AngleBetweenNeighbors_Adjacent 0.1414
Granularity_9_ImageAfterMath 0.1395
In the next set of analysis, we regress survival on gene expressions. The identified gene expressions and
clinical characteristics as well as their estimated coefficients are shown in Tables 4 (LUAD) and 5
(LUSC), respectively. Among the identified genes, there are “familiar” discoveries such as PIK3CG 29 and
RND330. In addition, there are also genes that have not yet been well examined in the literature, such as
DNMT2 and UQCRC2.
Table 4. Analysis of LUAD data: identified gene expressions and clinical characteristics associated with
overall survival and their estimated coefficients.
Gene expression Coef
Clinical
characteristic
Coef
CCNB1 0.0033 Sex 0.0011
CTSL 0.3694 Age 0.0173
GLI2 0.2555 Tumor_Size 0.0640
MFHAS1 -0.2228 Stage_Level_A -1.2460
PIK3CG -0.3782 Stage_Level_B -0.4012
RND3 0.1841 Stage_Level_C NA
Table 5. Analysis of LUSC data: identified gene expressions and clinical characteristics associated with
overall survival and their estimated coefficients.
Gene expression Coef
Clinical
characteristic
Coef
IL11 0.0526 Sex 0.4661
MUC1 0.0977 Age 0.0309
PIK3CG 0.0702 Tumor_Size -0.4890
PRKCA 0.1295 Stage_Level_A -0.7719
WDHD1 -0.1404 Stage_Level_B -0.6034
Stage_Level_C NA
When integrating the combined imaging effect with the combined gene expression effect in one Cox
model, for the LUAD data, we obtain regression coefficients 0.9842 (imaging feature, p-value=2.12e-6)
and 0.4726 (gene expression, p-value=5.36e-9). For the LUSC data, we obtain regression coefficient
0.9709 (imaging feature, p-value=5.55e-9) and 0.8769 (gene expression, p-value=2.04e-3).
In the random-splitting based prediction evaluation, for the LUAD data, the median prediction C-index
values are 0.6202 (imaging features), 0.6864 (gene expressions), and 0.6823 (combined). For the LUSC
data, the median prediction C-index values are 0.5466 (imaging features), 0.5606 (gene expressions), and
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0.5511 (combined). More detailed information, for example on the prediction C-index of each split, is
available from the authors.
Remarks: In the separate survival analysis with imaging features and gene expressions, relevant effects
have been identified. For imaging features, extensive additional research will be needed to fully
comprehend the identified variables. We note that this has been noted in the literature 8. A possible
solution is to use low-dimensional features, which may have more lucid interpretations 31. However, a
drawback is that they may contain (much) less information. In the analysis of gene expression data, the
“familiarity” of findings may suggest the validity of analysis to a certain extent. However, it is noted that
more definitive validation will be needed to confirm the findings. The survival analysis with imaging and
gene expression signatures as covariates seems to suggest that the two types of measurements have
independent effects. In the random splitting-based evaluation, it is observed that for LUAD, gene
expression has moderate predictive performance, and imaging data has moderate/weak predictive
performance. For LUSC, both types of measurements have weak predictive performance. For both
datasets, gene expression has better performance, which is sensible considering the genetic nature of lung
cancer (and other cancers too). Although both LUAD and LUSC are lung cancer subtypes, we observe
significantly different results, which can be attributable to the complexity of cancer and suggest that there
may not be a definitive conclusion applicable to all cancers. The random splitting evaluation further
suggests that integrating the two types of signatures in an additive manner may not further improve
prediction, which seems to “contradict” the analysis above. There can be multiple interpretations for this
finding. First, the distinction between estimation and prediction should be made – a “good” estimation
result may not directly translate into a good prediction. Second, the estimation analysis is repeatedly
based on the same data, and there is a risk of over fitting. Third, in the random splitting evaluation, both
the training and evaluation are based on fewer observations. An improvement that can be potentially
observed with a larger dataset may not be observable with a smaller dataset. It is also noted that
penalization and some other sparse approaches have been designed for estimation and may not be ideal
for prediction, which may explain the less satisfactory prediction performance observed here.
4.2 Association of gene expressions and histopathological imaging features
We first regress imaging features on gene expressions. Detailed information on the identified gene
expressions and their estimated coefficients are provided in the Supplementary Materials. In Figure 2, we
show the heatmaps of the estimated coefficients. Briefly, for the LUAD data, in the 50*221 coefficient
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matrix, a total of 7,735 elements are nonzero. A total of 35 genes, including MKI67, ACSL6, NFX1, and
WIF1, are identified as associated with 221 imaging features. For the LUSC data, a total of 6,618
elements are nonzero. A total of 28 genes, including ARAF, BCL7A, NXF1, and TP53, are identified as
associated with 221 imaging features.
Figure 2: Heat map of modeling imaging features using gene expressions. Upper panel: LUAD; Lower
panel: LUSC.
Figure 3: Analysis of predicting imaging features using gene expressions: Mean and standard deviation
plots of correlation coefficients from 100 random splits. Left: LUAD. Right: LUSC.
The random-splitting based prediction evaluation results are summarized in Figure 3, where we sort
performance, from worst to best, across imaging features. More detailed numerical results are provided in
the Supplementary Materials.
Remarks: The regression analysis suggests that certain gene expressions are connected to imaging
features. This observation is sensible considering, as described in Introduction, that properties reflected in
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imaging features are regulated by molecular changes to a certain extent. On the other hand, the prediction
results, as shown in Figure 3, suggest that such associations are mostly weak to moderate. The majority of
information in imaging features cannot be readily explained by gene expressions, and this finding differs
from that in some published studies 32-34. It is unclear whether such a difference is attributable to the
complexity of cancer, difference in analysis approach, or other factors. More exploration, especially a
direct comparison, will be needed.
5. Conclusions
Accurately modeling prognosis and other cancer outcomes will remain an important problem for a long
time to come. Histopathological imaging data has a great potential. It would be “safe” to predict an
increase in imaging feature-based modeling and research that integrate imaging, molecular, clinical, and
other data. In this study, we have demonstrated how to analyze/integrate these data under the same ground
using advanced statistical techniques. More methodological developments can be built on this article. Our
finding on the two lung cancer subtypes has suggested that more sophisticated integration may be needed.
The revealed interconnections between imaging and molecular features warrants additional investigation.
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